Antibiotic resistance threatens modern medicine as we know it. We urgently need new antimicrobials and better strategies to preserve their efficacy.
Anti-virulence drugs offer the potential to disarm bacteria, rather than killing them or preventing growth. This promises infection control but in a manner that should confer a reduced selection pressure for resistance development.
DiSulfide Bond (DSB) proteins are a family of foldases that catalyse the oxidative folding of virulence proteins in many bacterial species. DSB proteins engage in protein-protein interactions that we aim to characterise and disrupt using protein crystallography and structure based drug discovery approaches. As part of this endeavour we have assembled a sizeable structural library of diverse bacterial DsbA proteins. I will discuss our rational approaches to the identification of small molecule inhibitors targeting DsbA proteins in Burkholderia pseudomallei, Pseudomonas aeruginosa and Escherichia coli, as well as progress in the structural and biochemical examination of DSB partner protein interactions, as part of a broader aim to characterise this fascinating family of antimicrobial targets.